PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.
Daisuke YabeYoshiyuki HamamotoDaiji KawanamiRimei NishimuraYasuo TerauchiHanan AmadidUffe Christian BraaeAtheline Major-PedersenRyo SuzukiPublished in: Journal of diabetes investigation (2024)
and bodyweight were significantly reduced from baseline in adults initiating oral semaglutide, including those aged ≥75 years, with no new safety concerns.
Keyphrases